Differences in intraoperative sampling during meningioma surgery regarding CNS invasion – Results of a survey on behalf of the EANS skull base section

[1]  J. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019. , 2022, Neuro-oncology.

[2]  G. Umana,et al.  Updated Systematic Review on the Role of Brain Invasion in Intracranial Meningiomas: What, When, Why? , 2022, Cancers.

[3]  S. Wolfsberger,et al.  Clinico-pathologic predictors of dismal course in atypical meningiomas: a retrospective single-centre analysis. , 2022, Journal of neurosurgical sciences.

[4]  F. Ducray,et al.  Clinical and pathological impact of an optimal assessment of brain invasion for grade 2 meningioma diagnosis: lessons from a series of 291 cases , 2022, Neurosurgical Review.

[5]  Junlin Zhou,et al.  Nomogram based on MRI can preoperatively predict brain invasion in meningioma , 2022, Neurosurgical Review.

[6]  J. Honegger,et al.  Increased proliferation is associated with CNS invasion in meningiomas , 2021, Journal of Neuro-Oncology.

[7]  J. Schittenhelm,et al.  Brain Invasion in Meningioma—A Prognostic Potential Worth Exploring , 2021, Cancers.

[8]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[9]  J. Krauss,et al.  The prognostic significance of clinicopathological features in meningiomas: Microscopic brain invasion can predict patient outcome in otherwise benign meningiomas , 2021, Neuropathology and applied neurobiology.

[10]  A. Perry.  The definition and role of brain invasion in meningioma grading: Still controversial after all these years. , 2021, Free neuropathology.

[11]  J. Honegger,et al.  H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort , 2020, Neuro-oncology.

[12]  J. Honegger,et al.  CNS Invasion in Meningioma—How the Intraoperative Assessment Can Improve the Prognostic Evaluation of Tumor Recurrence , 2020, Cancers.

[13]  David T. W. Jones,et al.  CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas , 2020, Acta Neuropathologica.

[14]  A. von Deimling,et al.  Microscopic brain invasion in meningiomas previously classified as WHO grade I is not associated with patient outcome , 2019, Journal of Neuro-Oncology.

[15]  U. Wildförster,et al.  Brain invasion in meningiomas: does surgical sampling impact specimen characteristics and histology? , 2019, Neurosurgical Review.

[16]  W. Heindel,et al.  Prediction of brain invasion in patients with meningiomas using preoperative magnetic resonance imaging , 2018, Oncotarget.

[17]  M. Weller,et al.  Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence , 2018, Acta Neuropathologica.

[18]  C. Mawrin,et al.  Brain invasion in meningiomas—clinical considerations and impact of neuropathological evaluation: a systematic review , 2017, Neuro-oncology.

[19]  M. Weller,et al.  EANO guidelines for the diagnosis and treatment of meningiomas. , 2016, The Lancet. Oncology.

[20]  K. Plate,et al.  Brain invasion in otherwise benign meningiomas does not predict tumor recurrence , 2016, Acta Neuropathologica.

[21]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[22]  K. Aldape,et al.  TERT Promoter Mutations and Risk of Recurrence in Meningioma. , 2016, Journal of the National Cancer Institute.

[23]  J. Pižem,et al.  Brain invasion assessability in meningiomas is related to meningioma size and grade, and can be improved by extensive sampling of the surgically removed meningioma specimen. , 2014, Clinical neuropathology.

[24]  S. Lönn,et al.  Long-term 25-year follow-up of surgically treated parasagittal meningiomas. , 2011, World neurosurgery.

[25]  D. Louis,et al.  Bone involvement predicts poor outcome in atypical meningioma. , 2008, Journal of neurosurgery.

[26]  OUP accepted manuscript , 2022, Neuro-Oncology.